Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.

Medicare Advantage exits, rising ACA premiums, a Medicare for America bill, and a Medicaid work rule ruling frame health policy on Election Day.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.

Nathan Estrada, DPT, explains which patients, including those with multiple sclerosis, may benefit from footwear that adapts to gait.

Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.